125 related articles for article (PubMed ID: 8277212)
1. Radioimmunotherapy of gastrointestinal cancer and glioblastomas.
Riva P; Tison V; Arista A; Sturiale C; Franceschi G; Riva N; Casi M; Moscatelli G; Campori F; Spinelli A
Int J Biol Markers; 1993; 8(3):192-7. PubMed ID: 8277212
[TBL] [Abstract][Full Text] [Related]
2. Long-term outcome of patients with WHO Grade III and IV gliomas treated by fractionated intracavitary radioimmunotherapy.
Reulen HJ; Poepperl G; Goetz C; Gildehaus FJ; Schmidt M; Tatsch K; Pietsch T; Kraus T; Rachinger W
J Neurosurg; 2015 Sep; 123(3):760-70. PubMed ID: 26140493
[TBL] [Abstract][Full Text] [Related]
3. Treatment of intracranial human glioblastoma by direct intratumoral administration of 131I-labelled anti-tenascin monoclonal antibody BC-2.
Riva P; Arista A; Sturiale C; Moscatelli G; Tison V; Mariani M; Seccamani E; Lazzari S; Fagioli L; Franceschi G
Int J Cancer; 1992 Apr; 51(1):7-13. PubMed ID: 1373410
[TBL] [Abstract][Full Text] [Related]
4. A Phase II study of anti-epidermal growth factor receptor radioimmunotherapy in the treatment of glioblastoma multiforme.
Li L; Quang TS; Gracely EJ; Kim JH; Emrich JG; Yaeger TE; Jenrette JM; Cohen SC; Black P; Brady LW
J Neurosurg; 2010 Aug; 113(2):192-8. PubMed ID: 20345222
[TBL] [Abstract][Full Text] [Related]
5. Local treatment of malignant gliomas by direct infusion of specific monoclonal antibodies labeled with 131I: comparison of the results obtained in recurrent and newly diagnosed tumors.
Riva P; Arista A; Franceschi G; Frattarelli M; Sturiale C; Riva N; Casi M; Rossitti R
Cancer Res; 1995 Dec; 55(23 Suppl):5952s-5956s. PubMed ID: 7493376
[TBL] [Abstract][Full Text] [Related]
6. Combined treatment of glioblastoma patients with locoregional pre-targeted 90Y-biotin radioimmunotherapy and temozolomide.
Bartolomei M; Mazzetta C; Handkiewicz-Junak D; Bodei L; Rocca P; Grana C; Maira G; Sturiale C; Villa G; Paganelli G
Q J Nucl Med Mol Imaging; 2004 Sep; 48(3):220-8. PubMed ID: 15499296
[TBL] [Abstract][Full Text] [Related]
7. Treatment of recurrent glioblastoma multiforme with GliaSite brachytherapy.
Chan TA; Weingart JD; Parisi M; Hughes MA; Olivi A; Borzillary S; Alahakone D; Detorie NA; Wharam MD; Kleinberg L
Int J Radiat Oncol Biol Phys; 2005 Jul; 62(4):1133-9. PubMed ID: 15990019
[TBL] [Abstract][Full Text] [Related]
8. Intratumoral delivery of mitoxantrone in association with 90-Y radioimmunotherapy (RIT) in recurrent glioblastoma.
Boiardi A; Bartolomei M; Silvani A; Eoli M; Salmaggi A; Lamperti E; Milanesi I; Botturi A; Rocca P; Bodei L; Broggi G; Paganelli G
J Neurooncol; 2005 Apr; 72(2):125-31. PubMed ID: 15925992
[TBL] [Abstract][Full Text] [Related]
9. Locoregional radioimmunotherapy in selected patients with malignant glioma: experiences, side effects and survival times.
Goetz C; Riva P; Poepperl G; Gildehaus FJ; Hischa A; Tatsch K; Reulen HJ
J Neurooncol; 2003 May; 62(3):321-8. PubMed ID: 12777085
[TBL] [Abstract][Full Text] [Related]
10. Glioblastoma therapy by direct intralesional administration of I-131 radioiodine labeled antitenascin antibodies.
Riva P; Arista A; Sturiale C; Tison V; Lazzari S; Franceschi G; Spinelli A; Casi M; Sarti G; Campori F
Cell Biophys; 1994; 24-25():37-43. PubMed ID: 7537631
[TBL] [Abstract][Full Text] [Related]
11. Pre-targeted locoregional radioimmunotherapy with 90Y-biotin in glioma patients: phase I study and preliminary therapeutic results.
Paganelli G; Bartolomei M; Ferrari M; Cremonesi M; Broggi G; Maira G; Sturiale C; Grana C; Prisco G; Gatti M; Caliceti P; Chinol M
Cancer Biother Radiopharm; 2001 Jun; 16(3):227-35. PubMed ID: 11471487
[TBL] [Abstract][Full Text] [Related]
12. Permanent iodine-125 interstitial implants for the treatment of recurrent glioblastoma multiforme.
Patel S; Breneman JC; Warnick RE; Albright RE; Tobler WD; van Loveren HR; Tew JM
Neurosurgery; 2000 May; 46(5):1123-8; discussion 1128-30. PubMed ID: 10807244
[TBL] [Abstract][Full Text] [Related]
13. Evaluating changes in stable chromosomal translocation frequency in patients receiving radioimmunotherapy.
Wong JY; Wang J; Liu A; Odom-Maryon T; Shively JE; Raubitschek AA; Williams LE
Int J Radiat Oncol Biol Phys; 2000 Feb; 46(3):599-607. PubMed ID: 10701739
[TBL] [Abstract][Full Text] [Related]
14. Low-dose rate stereotactic iodine-125 brachytherapy for the treatment of inoperable primary and recurrent glioblastoma: single-center experience with 201 cases.
Kickingereder P; Hamisch C; Suchorska B; Galldiks N; Visser-Vandewalle V; Goldbrunner R; Kocher M; Treuer H; Voges J; Ruge MI
J Neurooncol; 2014 Dec; 120(3):615-23. PubMed ID: 25151509
[TBL] [Abstract][Full Text] [Related]
15. [Initial experiences with adjuvant locoregional radioimmunotherapy using 131I-labeled monoclonal antibodies against tenascin (BC-4) for treatment of glioma (WHO III and IV)].
Pöpperl G; Götz C; Gildehaus FJ; Yousry TA; Reulen HJ; Hahn K; Tatsch K
Nuklearmedizin; 2002 Jun; 41(3):120-8. PubMed ID: 12109031
[TBL] [Abstract][Full Text] [Related]
16. Re-irradiation of recurrent glioblastoma multiforme using 11C-methionine PET/CT/MRI image fusion for hypofractionated stereotactic radiotherapy by intensity modulated radiation therapy.
Miwa K; Matsuo M; Ogawa S; Shinoda J; Yokoyama K; Yamada J; Yano H; Iwama T
Radiat Oncol; 2014 Aug; 9():181. PubMed ID: 25123357
[TBL] [Abstract][Full Text] [Related]
17. CT-guided interstitial HDR-brachytherapy for recurrent glioblastoma multiforme: a 20-year single-institute experience.
Chatzikonstantinou G; Zamboglou N; Archavlis E; Strouthos I; Zoga E; Milickovic N; Hilaris B; Baltas D; Rödel C; Tselis N
Strahlenther Onkol; 2018 Dec; 194(12):1171-1179. PubMed ID: 30203110
[TBL] [Abstract][Full Text] [Related]
18. 131I radioconjugated antibodies for the locoregional radioimmunotherapy of high-grade malignant glioma--phase I and II study.
Riva P; Franceschi G; Frattarelli M; Riva N; Guiducci G; Cremonini AM; Giuliani G; Casi M; Gentile R; Jekunen AA; Kairemo KJ
Acta Oncol; 1999; 38(3):351-9. PubMed ID: 10380827
[TBL] [Abstract][Full Text] [Related]
19. Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results.
Reardon DA; Akabani G; Coleman RE; Friedman AH; Friedman HS; Herndon JE; McLendon RE; Pegram CN; Provenzale JM; Quinn JA; Rich JN; Vredenburgh JJ; Desjardins A; Gururangan S; Badruddoja M; Dowell JM; Wong TZ; Zhao XG; Zalutsky MR; Bigner DD
J Clin Oncol; 2006 Jan; 24(1):115-22. PubMed ID: 16382120
[TBL] [Abstract][Full Text] [Related]
20. New approach in delivering chemotherapy: locoregional treatment for recurrent glioblastoma (rGBM).
Boiardi A; Eoli M; Salmaggi A; Lamperti E; Botturi A; Broggi G; Bartolomei M; Silvani A
J Exp Clin Cancer Res; 2003 Dec; 22(4 Suppl):123-7. PubMed ID: 16767918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
